Regulatory Webinars
-
Addressing Opportunities And Challenges In Digital Health Data
10/22/2024
Experts from diverse industry sectors unpack key points from the FDA’s final guidance on Digital Health Technologies (DHT) for remote data collection in clinical investigations.
-
Driving Product Launch Success In Europe
10/21/2024
Explore key steps for preparing your medicinal product for the European market, including insights on challenges, timelines, and a success story.
-
Harnessing The Power Of AI In Health Evidence Generation Strategy
10/21/2024
Explore applications and limitations for artificial intelligence (AI) in healthcare as decision-makers determine whether to adopt the software in their environments.
-
The Next Frontier In Early Phase Oncology Trials
10/18/2024
This session explores the pivotal role of First-in-Human and early phase oncology trials in drug development, emphasizing the importance of comprehensive planning for successful execution.
-
Anticipating And Adapting At Every Step Of Development
10/18/2024
Review how Parexel's Oncology Site Alliance Network can support the accelerated timelines and flexibility required in early phase oncology studies.
-
Oncology Clinical Trials Key Considerations: Planning For Success
10/18/2024
Chief Scientific Officer Gabriel Kremmidiotis and CEO Yvonne Lungershausen from Avance Clinical delve into key strategies for conducting successful early-phase oncology trials for biotechs.
-
From Crisis To Confidence In Medical Writing: Ensuring Smooth Regulatory Submissions
10/8/2024
Explore some of the major challenges that medical writing submission specialists face today and present strategies that can consistently set the stage for success.
-
FDA's Vision On PRO Collection For RWE
9/24/2024
In this presentation, a distinguished panel of experts illuminates the crucial role of patient-reported outcomes (PROs) in shaping regulatory decisions and drug development strategies, particularly in light of FDA expectations.
-
The Diversity Mandate: Effective Strategies in Clinical Trials
9/5/2024
The June 2024 release of the FDA’s guidance related to diversity in clinical trials gives more direction to the industry on this ongoing concern and details what trials need Diversity Action Plans (DAPs), what should be included, and how to submit them. Will this be the turning point that shifts the conversation surrounding diversity from marketing rhetoric to actual implementations?
-
TMF SUMMER SHORTS: House Of The Inspector
8/29/2024
Discover key steps you can take to not just survive an inspection, but take the TMF Throne.